Eckhard Niemeler Joins Nouscom As Chief Business Officer
Nouscom appoints Eckhard Niemeler as CBO to drive growth and strategic partnerships, advancing its neoantigen cancer immunotherapy pipeline.
Breaking News
Dec 03, 2024
Simantini Singh Deo

Nouscom, a clinical-stage immuno-oncology company specialising in off-the-shelf and personalised neoantigen cancer immunotherapies, has announced the appointment of Eckhard Niemeler as Chief Business Officer (CBO). Mr. Eckhard holds over two decades of experience in corporate development and strategic leadership within the life sciences sector. Eckhard will closely collaborate with Nouscom's leadership team to drive the company’s growth and strategic initiatives.
Dr. Marina Udier, CEO of Nouscom, commented on the appointment, "We are delighted to welcome Eckhard to Nouscom. His proven track record in forging collaborations with leading pharmaceutical and biotech companies aligns perfectly with our vision for growth and innovation. The next 12 months will be an exciting time for Nouscom as we anticipate key data readouts from clinical trials with our lead asset, NOUS-209, in DMMR/MS metastatic CRC and in Lynch Syndrome carriers.
I look forward to working with Eckhard and the leadership team to shape the next phase of growth for the company, leveraging both our pipeline opportunities, such as NOUS-PEV, and the broad potential of our innovative platform."
Mr. Niemeler previously served as Chief Business and Innovation Officer at UNION Therapeutics A/S. He led business and corporate development efforts, including licensing, strategic alliances, and management of key partnerships at UNION Therapeutics. His contributions were pivotal in advancing UNION’s portfolio and corporate strategy. Prior to that, he held senior positions at Pieris Pharmaceuticals, forging strategic collaborations with industry leaders such as AstraZeneca, Roche/Genentech, Seagen, and Servier. Earlier in his career, he managed licensing and partnerships at Gruenenthal Pharma and MorphoSys. He began his professional journey at McKinsey & Company, focusing on healthcare and life sciences. Mr. Niemeler holds a master’s in biotechnology and completed his thesis in Human Genome Sciences.
Mr. Eckhard Niemeier. CBO said, "I am excited to join Nouscom at such a key moment. The company's strong pipeline of off-the-shelf and personalised neoantigen cancer immunotherapies and innovative platforms presents great opportunities for external partnerships. I look forward to working with the team to unlock value and deliver potentially meaningful cancer treatments to patients."